We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland

By LabMedica International staff writers
Posted on 23 Jan 2023

Siemens Healthineers (Erlangen, Germany) has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. More...

The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders. Siemens has been active in Swords since 1966, supplying medical diagnostic equipment to hospitals and laboratories. The site currently manufactures hematology and immunoassay analyzers and supports the continuous innovation of current and new products and the development of laboratory automation software, exported to more than 50 countries across all continents. Siemens will be making a multi-million-euro investment in the site, enabling clinicians to optimize patient care by bringing new levels of precision, efficiency and reliability to the diagnostic laboratories that serve them.

The investment by Siemens will span multiple years and more than double the existing engineering team, transforming the site into an innovation hub, growing knowledge, providing new training opportunities and developing a pool of expertise in immunoassay technology. The center will push the boundaries of science and engineering. Improvements to existing diagnostic techniques will enhance disease detection capabilities with the goal of delivering faster, higher precision results with improved patient insights. This will help to meet the extremely high throughput and complex needs of hospitals and laboratories in Ireland as well as globally. The project is supported by the Irish government through IDA Ireland.

“The investment at Swords will build on our existing expertise in healthcare manufacturing, adding a critical research and development focus," states Dr Dennis Gilbert, Head of R&D for Siemens Healthineers Diagnostics. "Partnering with IDA has enabled us to move forward in ways that would not have otherwise been feasible and will allow us to pioneer breakthroughs in healthcare, helping hospitals and laboratories across the globe to diagnose disease more effectively and efficiently.

Related Links:
Siemens Healthineers 


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.